Noxopharm Ltd (ASX: NOX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Noxopharm Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Noxopharm Ltd (ASX: NOX)
Latest News
Share Gainers
Why Noxopharm, Orora, Ramelius, and Silver Lake shares are pushing higher
Healthcare Shares
ASX healthcare stock Noxopharm explodes 165% on FDA news
Healthcare Shares
This ASX healthcare share is surging 17% on a new FDA ruling
Earnings Results
Clinical trials not enough to stop Noxopharm (ASX:NOX) shares' 5% plunge on Monday
Share Market News
The Noxopharm (ASX:NOX) share price is jumping 6% after announcing a new CEO
Healthcare Shares
Here's why the Noxopharm (ASX: NOX) share price leapt 7% today
Share Gainers
Why is the Noxopharm (ASX:NOX) share price up 4% on Monday?
Share Gainers
Noxopharm (ASX:NOX) share price jumps 13% on COVID treatment update
Healthcare Shares
The Noxopharm (ASX:NOX) share price is soaring 7%
Healthcare Shares
Noxopharm (ASX:NOX) share price edges lower after clinical trial update
Share Gainers
Why the Noxopharm (ASX:NOX) share price is charging higher again
Share Market News
Why the Noxopharm share price rocketed 22% today
NOX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Noxopharm Ltd
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.
NOX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
14 Nov 2024 | $0.11 | $-0.02 | -16.67% | 150,000 | $0.11 | $0.11 | $0.11 |
13 Nov 2024 | $0.12 | $0.00 | 0.00% | 195,644 | $0.11 | $0.12 | $0.11 |
12 Nov 2024 | $0.12 | $0.02 | 19.05% | 176,719 | $0.11 | $0.12 | $0.11 |
11 Nov 2024 | $0.11 | $-0.01 | -9.09% | 66,300 | $0.11 | $0.11 | $0.11 |
08 Nov 2024 | $0.11 | $0.01 | 9.52% | 171,901 | $0.12 | $0.12 | $0.11 |
07 Nov 2024 | $0.11 | $-0.01 | -9.09% | 18,167 | $0.11 | $0.11 | $0.11 |
06 Nov 2024 | $0.11 | $0.01 | 9.52% | 160,524 | $0.11 | $0.12 | $0.11 |
05 Nov 2024 | $0.11 | $-0.03 | -23.08% | 915,685 | $0.13 | $0.13 | $0.11 |
04 Nov 2024 | $0.13 | $-0.01 | -7.41% | 350,786 | $0.13 | $0.13 | $0.13 |
01 Nov 2024 | $0.14 | $0.01 | 7.69% | 89,676 | $0.13 | $0.14 | $0.13 |
31 Oct 2024 | $0.13 | $0.00 | 0.00% | 125,583 | $0.13 | $0.14 | $0.13 |
30 Oct 2024 | $0.13 | $0.01 | 8.00% | 78,742 | $0.13 | $0.13 | $0.13 |
29 Oct 2024 | $0.13 | $-0.01 | -7.69% | 536,402 | $0.13 | $0.14 | $0.13 |
28 Oct 2024 | $0.13 | $-0.01 | -7.14% | 484,713 | $0.14 | $0.15 | $0.13 |
25 Oct 2024 | $0.14 | $0.01 | 7.69% | 692,717 | $0.13 | $0.14 | $0.13 |
24 Oct 2024 | $0.13 | $0.00 | 0.00% | 5,384 | $0.13 | $0.13 | $0.13 |
23 Oct 2024 | $0.13 | $0.01 | 8.00% | 237,608 | $0.13 | $0.13 | $0.13 |
22 Oct 2024 | $0.13 | $0.01 | 8.70% | 672,092 | $0.12 | $0.13 | $0.12 |
21 Oct 2024 | $0.12 | $0.00 | 0.00% | 16,197 | $0.12 | $0.12 | $0.12 |
18 Oct 2024 | $0.12 | $0.00 | 0.00% | 48,834 | $0.12 | $0.12 | $0.12 |
17 Oct 2024 | $0.12 | $0.01 | 9.09% | 533,912 | $0.11 | $0.12 | $0.11 |
16 Oct 2024 | $0.11 | $0.01 | 9.52% | 407,561 | $0.11 | $0.12 | $0.11 |
15 Oct 2024 | $0.11 | $-0.01 | -9.09% | 32,415 | $0.11 | $0.11 | $0.11 |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Frederick (Fred) Bart | Non-Executive DirectorNon-Executive Chairman | May 2020 |
Mr Bart was appointed the Managing Director of Textile Industries Australia in 1985. The Group employed over 1,200 people and distributed product to countries worldwide. The Company manufactured and distributed the majority of bed linen in Australia under brands like Sheridan and ACTIL. The Company was sold in 1987. In 1989, Mr Bart established and chairs a number of private companies under the umbrella of the Bart Group which covered hotels, retail, commercial and residential land development and technologies which still continue to operate. The Group today employs in excess of 1,000 people and is active in local and overseas markets. In 2013, Mr Bart became Director and majority shareholder of Immunovative Therapies Limited, a private Israeli company involved in the manufacture of vaccines for the treatment of certain forms of cancer. The Company has undertaken trials in both colorectal and liver cancers. He is Member of Risk Committee. Former directorships (last 3 years): Weebit Nano Limited - resigned 27 June 2023.
|
Mr Peter Ashley Marks | Non-Executive DirectorNon-Executive Deputy Chairman | Mar 2016 |
Mr Marks has over 35 years' experience in corporate advisory and investment banking. Over the course of his career, he has specialised in capital raising IPOs, cross border capital raisings, M&A transactions, corporate underwriting and venture capital transactions for companies based in Australia, the US and Israel. He has been involved in a range of transactions with a focus in the life-sciences, biotechnology, medical technology and high tech as well as the mining sector. Peter has served as an Executive and Non-Executive Director of a number of entities, many of which have been listed on the ASX, Nasdaq and AIM markets. He is Chair of Risk Committee.
|
Mr Boris Patkin | Non-Executive Director | Mar 2020 |
Mr Patkin brings market knowledge, thorough research and years of experience in investment markets and business consulting. As a financial and investment advisor, Boris has an understanding of industry trends and has insight into domestic and international markets. He specialises in the reconstruction of companies, investments and in international trade and is also an experienced business consultant in the medical and disruptive technology arena. He is a senior advisor with Morgans Financial Ltd. He is Member of Risk Committee.
|
Dr Gisela Mautner | Chief Executive OfficerManaging Director | Feb 2022 |
Dr Mautner has more than 20 years of leadership experience in global pharmaceutical organisations, including operational, medical and scientific advisory roles across therapeutic areas. During her career she held senior positions at global pharmaceutical companies like MSD (Merck), Bayer and Amgen in Germany as well as Australia.
|
Mr David James Franks | Company Secretary | Jan 2017 |
-
|
David James Franks | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Milligene Pty Ltd (The Ge and Pr Kelly Family A/C) | 34,249,106 | 11.72% |
Mrs Eleanore Goodridge | 13,050,000 | 4.47% |
Link Traders (Aust) Pty Ltd | 10,586,522 | 3.62% |
Citicorp Nominees Pty Ltd | 7,932,804 | 2.71% |
Mr Fred Bart | 7,507,813 | 2.57% |
Rgt Capital Fund No 5 (Noxo) Pty Ltd | 6,500,333 | 2.22% |
Kale Capital Corporation Limited | 4,997,437 | 1.71% |
Jamber Investments Pty Ltd (The Amber Schwarz Fam A/C) | 4,066,400 | 1.39% |
Rhlc Pty Limited (Rhlc S/F A/C) | 3,000,000 | 1.03% |
Mr Lizhong Yu | 2,918,000 | 1.00% |
Blackcourt (Nsw) Pty Limited (Lawsam Super Fund A/C) | 2,686,376 | 0.92% |
Mr Robert Thomas Lin | 2,500,000 | 0.86% |
Ogen Nominees Pty Ltd | 2,300,000 | 0.79% |
Halcyon Nominees Pty Ltd (Halcyon Super Fund A/C) | 2,000,000 | 0.68% |
Citicorp Nominees Pty Limited (120296 Infitude A/C) | 1,982,237 | 0.68% |
Mrs Sophie Ethel Gelski | 1,942,424 | 0.66% |
Mr Michael Shabat & Ms Meital Hana Shabat (M&M Shabat Super Fund A/C) | 1,843,000 | 0.63% |
Helium Management Pty Ltd (Helium S/F A/C) | 1,751,246 | 0.60% |
Berne No 132 Nominess Pty Ltd (331898 A/C) | 1,660,357 | 0.57% |
Ms Jin Qin Wang | 1,600,000 | 0.55% |